Elevation of soluble Fas (APO-1, CD95) ligand in natural aging and Werner syndrome

BioScience Trends

Volumn 2, Issue 3, 2008, Pages 124-127

  Goto, Makoto ^a  

^a TOIN UNIVERSITY OF YOKOHAMA   (Japan)

Author keywords

Aging; Apoptosis; Inflammaging; Soluble Fas ligand; Werner syndrome

Indexed keywords

C REACTIVE PROTEIN; FAS ANTIGEN;

ADOLESCENT; ADULT; AGED; AGING; ARTICLE; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; JAPAN; MALE; MIDDLE AGED; WERNER SYNDROME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; ANTIGENS, CD95; C-REACTIVE PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION; JAPAN; MALE; MIDDLE AGED; WERNER SYNDROME; YOUNG ADULT;

EID: 77952299154     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Kerr JF, Wyllie AH, Currie AR. Apoptosis:a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26:239-257. 126
2. Columbano A. Cell death: Current difficulties in discriminating apoptosis from necrosis in the context of physiological process in vivo. J Cell Biolchem 1995; 58:181-190.
3. Meier P, Finch A, Evan G. Apoptosis in development. Nature 2000; 407:796-801.
4. Rich T, Allen RL, Wyllie AH. Defying death after DNA damage. Nature 2000; 407:777-783.
5. Nagata S. Apoptosis by death factor. Cell 1997; 88:355-365.
6. Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J 1995; 14:1129-1135.
7. Andreoli TE. The apoptotic syndromes. Am J Med 1999; 107:488.
8. Savill J. Apoptosis in resolution of inflammation. J Leukoc Biol 1997; 61:375-380.
9. Shibata T, Nagata K, Kobayashi Y. A critical role of nitric oxide in preventing inflammation upon apoptotic cell clearance. J Immunol 2007; 179:3407-3411.
10. Uchiyama E, Kodaira T, Kurosaka K, Watanabe N, Kobayashi Y. Interaction of phagocytes with apoptotic cells leads to production of pro-inflammatory cytokines. Biochem Biophys Res Commun 1997; 239:799-803.
11. Lockshin RA, Zakeri ZF. Programmed cell death: new thoughts and relevance to aging. J Gerontol 1990; 45:B135-140.
12. Warner HR, Hodes RJ, Pocinki K. What does cell death have to do with aging? J Am Geriat Soc 1997; 45:1140-1146.
13. Zhou T, Edwards III CK, Mountz JD. Prevention of agerelated T cell apoptosis defect in CD2-fas-transgenic mice. J Exp Med 1995; 182:129-137.
14. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263:1759-1762.
15. Jodo S, Kobayashi S, Kayagaki N. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol 1997; 107:89-95.
16. Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hashimoto H. Soluble Fas (AP-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum 1997; 40:1126-1129.
17. Sahin M, Aydintug O, Tunc SE, Tutkak H, Naziroglu M. Serum soluble Fas levels in patients with autoimmune rheumatic diseases. Clin Biochem 2007; 40:6-10.
18. Hebert MJ, Masse M, Vignealt N. Soluble Fas is a marker of coronary artery disease in patients with end-stage renal disease. Am J Kidney Dis 2001; 38:1271-1276.
19. Masse M, Hebert MJ, Troyanov S. Soluble Fas is a marker of peripheral arterial occulusive disease in haemodialysis patients. Nephrol Dia Transplant 2002; 17:485-491.
20. Choi JW, Kim SK. Relationships of soluble APO-1 (Fas/ CD95) concentrations, obesity, and serum lipid parameters in healthy adults. Ann Clin Lab Sci 2005; 35:290-296.
21. Knipping E, Debatin KM, Stricker K, Heilig B, Eder A, Krammer PH. Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias. Blood 1995; 85:1562-1569.
22. Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002; 16:508-519.
23. Van der Meer IM, Oei HHS, Hofman A, Pols HAP, de Jong FH, Witteman JCM. Soluble Fas, a mediator of apoptosis, C-reactive protein, and coronary and extracoronary atherosclerosis: The Rotterdam coronary calcification study. Atherosclerosis 2006; 189:464-469.
24. Seishima M, Takemura M, Saito K, Sano H, Minatoguchi S, Fujiwara H, Hachiya T, Noma A. Highly sensitive ELISA for soluble Fas in serum: increased soluble Fas in the elderly. Clin Chem 1996; 42:1911-1914.
25. Kipling D, Davis T, Ostler EL, Faragher RG. What can progeroid syndromes tell us about human aging? Science 2004; 305:1426-1431.
26. Martin GM. Clonal alterartion of somatic cells in aging mammals: a review of supportive evidence and its biomedical significance. Ann N Y Acad Sci 2007; 1119:1-8.
27. Kyng KJ, May A, Kolvraa S, Bohr VA. Gene expression profiling in Werner syndrome closely resembles that of normal aging. Proc Natl Acad Sci USA 2003; 100:12259-12264.
28. Goto M. Clinical characteristics of Werner syndrome and other premature aging syndromes: pattern of aging in progeroid syndromes. In From premature gray hair to helicase-Werner syndrome: Implications for aging and cancer. Edited by Goto M, Miller RW. Monograph on Cancer Research 2001; 49:27-39.
29. Goto M. Hierarchical deterioration of body systems in Werner syndrome: Implications for normal ageing. Mech Age Dev 1997; 98:239-254.
30. Goto M, Horiuchi Y, Sasazuki T. Family analysis of Werners syndrome: a survey of 42 Japanese families with a review of the literature. Clin Genet 1981; 19:8-15.
31. Satoh M, Imai M, Sugimoto M, Goto M, Furuichi Y. Prevalence of Werners syndrome heterozygotes in Japan. Lancet 1999; 353:1766.
32. Goto M. Immunosenescent features of human segmental progeroid syndrome:Werners syndrome. Aging Immunol Infect Dis 1992; 3:203-213.
33. Goto M, Kato Y. Hypercoagulable state indicates an additional risk factor for atherosclerosis in Werners syndrome. Thromb Haemost 1995; 73:576-578.
34. Goto M. Werners syndrome: From clinics to genetics. Clin Exp Rheumatol 2000; 18:760-766.
35. Ohsugi I, Imamura O, Satoh M, Sugawara M, Goto M, Sugimoto M, Furuichi Y. Overexpression of mRNAs of TGFβ-1 and related genes in fibroblasts of Werner syndrome patients. Mech Age Dev 2000; 155:189-198.
36. Tanabe M, Goto M. Elevation of serum hyaluronan level in Werners syndrome. Gerontol 2001; 47:77-81.
37. Yokote K, Hara K, Mori S, Kadowaki T, Saito Y, Goto M. Dysadipocytokinemia in Werner syndrome and its recovery by treatment with pioglitazone. Diabetes Care 2004; 27:2562-2563.
38. Goto M, Yamabe M, Shiratori M, Okada M, Kawabe T, Matsumoto T, Sugimoto M, Furuichi Y. Immunological diagnosis of Werner syndrome by down-regulated and truncated gene products. Hum Genet 1999; 105:301-307.
39. Endo S, Inada k, Takakuwa T, Kasai T, Yamada Y, Wakabayashi G, Niimi M, Suzuki T, Taniguchi S. Nitrite/ nitrate(NOx) and sFas antigen levels in patients with multiple organ failure. Res Commun Mol Path Pharma 1996; 92:253-256.
40. Goto M, Miller RW, Ishikawa Y, Sugano H. Excess of rare cancers in Werner syndrome (adult progeria). Cancer Epidemiol Biomarkers Prev 1996; 5:239-246.
41. Hashimoto H, Tanaka M, Suda T, Tomita T, Hayashida K, Takeuchi E, Kaneko M, Tanaka H, Nagata S, Ochi T. Spluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis. Arth Rheum 1998; 41:657-662.
42. Uchiyama E, Kodaira T, Kurosaka K, Yang D, Watanabe N, Kobayashi Y. Interaction of phagocytes with apoptotic cells leads to production of pro-inflammatory cytokines. Biochem Biophys Res Commun 1997; 239:799-803.
43. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-867.
44. Van den Biggelaar AHJ, de Craen AJM, Gussekloo J, Huizinga TWJ, Heijmans BT, Frolich M, Kirkwood TBL, Westendorp RGJ. Inflammation underlying cardiovasculair mortality is a late consequence of evolutionary programming. FASEB J 2004; 18:1022-1024.
45. Salvioli S, Capri M, Valensin S, Tieri P, Monti D, Ottaviani E, Franceschi C. Inflammaging, cytokines and aging: state of the art, new hypotheses on the role of mitochondria and new perspectives from systems biology. Curr Pharm Des 2006; 12:3161-3171.